• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies

    Waters Corp. Acquires Light Scattering Company Wyatt Technology
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Traceability & 2D Barcodes

    Complex in Complex – New Hopes for Better Drug Delivery in Topical Dosage Formulation

    Proactive Resource Group Offers DSCSA Services for Pharma Companies

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    TaiMed Biologics

    CMC Pharmaceuticals

    Societal CDMO

    Almac Group

    Lannett CDMO
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    TaiMed Biologics

    CMC Pharmaceuticals

    Societal CDMO

    Almac Group

    Lannett CDMO
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Some Changes in Formulation Paradigms

    Old ways are slowly changing with the introduction of PAT and QbD

    Some Changes in Formulation Paradigms
    Emil W. Ciurczak, DoraMaxx Consulting04.10.18
    Back in the late 1970s, I was forced, as the AR&D manager, to assume control of a “dicey” QC department at a non-Pharma company. I had to surrender my best “sous-chemist” to become the new supervisor, so I was a little annoyed. I addressed the QC group, telling them that they could insult me, my family, my pets, but two phrases would get them terminated: 1) “We’ve always done it this way” or 2) “We’ve never done it that way.” I pointed out that, if “this way” had worked, I wouldn’t have been forced to take over and have them do it “that way.”

    How does this tale relate to the manner in which small molecule Pharma formulators make their products? Well, I have stated on more than one occasion, that someone who retired from a production job in 1965 could easily come back to work today and, with a few days’ training, be up to speed. If you think religious doctrine or Congress moves slowly to change, just observe pharmaceutical formulators, where it seems to be: “if it was good enough for dad, it’s good enough for me.” Spoiler alert: Why change any procedures when Pharma can charge whatever it wants to cover costs?

    When the Pure Food and Drug Act, which created the FDA, came into existence, it made two assumptions: 1) physicians knew about drugs and 2) pharmacists knew how to put them into dosage forms. Considering the number of commercial drugs available at that time, the first part was true enough. Although today, an honest physician will admit they mostly know about drugs from company-sponsored seminars—trips to the Bahamas or Puerto Rico—and sales brochures. And, as for the personnel in a production facility, it is staffed and run by pharmacists.

    That second part made sense when most drugs were made in the back rooms of corner pharmacies. They were rolled into little balls (pills) or tapped into capsule shells, both hand-prepared and labor intensive. The earliest real tablets were made in commercial facilities, but at a slow enough rate and in small enough numbers and formulations that the converted “corner pharmacist” could formulate via “hunt and peck” R&D. When I started in 1970, I used to joke that “method development” consisted of “if 0.5% magnesium stearate doesn’t work, try 0.75%.”

    As more and more drugs were discovered and more and more doses were needed—a few thousand to a few million—the frenzied world of formulations was a “wild west” show. As pharmacy degrees went from two years in the “old days” to four years or five years, the pharmacists were trained, more and more, in school, not “on-the-job.” However, many of the same ideas persisted: Start small, work up, guess and pray for pilot studies to work; reformulate when they didn’t. And, along the way, some actually began using “Physical Pharmacy.” That is, some began to worry about what went on during the steps—blending, granulating—in a more materials-savvy way. 

    Nonetheless, even today, you can step into a production facility, swing a dead possum while wearing a blindfold, and strike a dozen pharmacists, yet not be able to find a Materials Scientist with a small nuclear charge. Yes, this is slowly changing with the introduction of PAT and QbD, but mostly in the larger, proprietary companies. Generics and CMOs are still trudging along the well-worn path (rut?) as in years past.

    Fortunately, the “path to enlightenment” (a Zen pharmaceutical approach?) is pretty much the same, no matter how large the company. I did not use the term enlightenment lightly. There are large gaps in the knowledge of the products we make and sell. The first is, we do not have control over our excipients and, in cases where the API is supplied by a client company, that, too. We still receive a shipment of, for example, lactose. We can either accept the certificate of analysis (CofA)—bad choice—or do some/all tests in-house. In either case, we can only accept or reject the batch. In very few cases, the company has some type of agreement with the supplier, based on knowledge of the process involved.
    What can be done to increase our chances of getting a “proper” lot of excipients? Well, as mentioned previously, upon generating your PAT/QbD committee, include some RM suppliers. They need not be in any proprietary discussions, just be told that it will be, for example, a 5% API, immediate release capsule or a 15%, continuous-release tablet. As your formulators understand via design of experiments the parameters needed for the dosage form, the suppliers can become “partners” and work to supply the needed material parameters. As an example, if “flowability” based on shape, surface tension and morphology is important, the supplier(s) can (for a fee?) put aside any batch that meets the specification required. Worst case, the CMO has too many batches of “prime” excipient, which could probably be used for other, less excipient sensitive products. But, you would never be out of the best material or have to use a “lesser” material for your critical product.

    As for the formulations portion of this infomercial, we need to examine the modus operandi, thereof. Assuming, for the moment, that we have experienced formulators building the dosage form. These people do preliminary pre-formulation studies, choose the release mechanism—immediate or continuous release tabs—dose size/API level, coating or no coating, etc. They proceed to perform bench-level experiments, then move on to pilot plant-sized batches, and finally, move to production-sized lots. There are several problems with this approach, namely, it is time-consuming and costly, may not develop the best dosage form, and you may not have the longest expiry date.

    There is a tendency in our industry to have “silos.” One effect is that we treat the API as a fait accompli, with only one possible form for doses. The organic chemists who synthesize the molecule are not interested and seldom know about the destination of their product; they simply try for the highest yield. They seldom give formulators choices of polymorphs, salts (Cl-, SO4-2, as co-ions), particle sizes, etc.

    When formulators perform pre-formulation, practicality forces them to merely make 50:50 mixes of each excipient with API, limiting the potential effects of various salts/polymorphs in the data bank. If formulators were allowed to “dream,” they would likely wish to see the effects of multiple interactions—e.g., API plus lactose, plus starch, plus talc. Sadly, using traditional pre-formulation techniques, involving sacrificing samples at time points and analyzing with TLC or HPLC, causes time constraints that do not allow multi-excipient or multi-API form testing.

    If we extend the concepts of PAT/QbD, namely design of experiment (DoE), coupled with modern spectroscopy, we can, indeed, perform meaningful pre-formulation studies. If we use, for example, NIRS or Raman to examine samples, we can increase the number of mixtures by a large factor. The multiple mixtures can be examined, non-destructively, daily, searching for potential interactions. Any sample that shows changes can be analyzed and any degradation plotted versus time. The good news is that we may also see some excipients “protecting” the API from degradation. This approach will give far more information to skilled formulators to build the best formulation. It will also give hints as to the long-term stability of the eventual dosage form.

    Assuming a full QbD program, this data almost obviates much of the work for a DoE on the finished dose. When the Design Space—parameters of pressure, mixing, etc.—is established, the exact production conditions of any lot may be coupled with results of stability tests for that lot. If we can show (validate) that a narrower set of parameters produces more stable products, we could apply for a longer expiry day, potentially saving a small fortune in product recalls. To fully utilize this approach, the same measurement technique used in preformulation may be applied here. Instead of merely testing 10-20 tablets for each bottle, all 50-100 or more may be examined by Raman or NIRS and a better picture of stability produced. Namely, we can state that, for example, lot A had 10 “different” tabs at one year, lot B, 5 “different,” lot C, 20 “different,” and so forth. These can be assayed to confirm whether the differences were physical—affecting dissolution—or chemical—affecting safety.

    Of course, the actual DoE, itself meant to be run on “production sized” lots, is far faster possibly by months using continuous manufacturing (CM) equipment. Also, since there is no pilot plant size in CM, all batches are “production level-sized” by merely running the set-up longer. These smaller lots are both less expensive by a factor of 10 and can be completed in days, not weeks. A win-win-win situation, no? 


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • Stability
    • generics
    • facility
    • Tablet
    Suggested For You
    Trust, but Verify Trust, but Verify
    API Development Trends API Development Trends
    Spray Drying: A Proven Approach to Enhance the Solubility of APIs Spray Drying: A Proven Approach to Enhance the Solubility of APIs
    Outsourcing the Manufacture of Clinical Trial APIs Outsourcing the Manufacture of Clinical Trial APIs
    Choosing and Managing a CDMO Choosing and Managing a CDMO
    Global Outsourcing Trends Global Outsourcing Trends
    Xellia’s Cleveland Manufacturing Facility is Commercially Operational Xellia’s Cleveland Manufacturing Facility is Commercially Operational
    Colorcon Qualifies as a Preferred Supplier with the National Animal Supplement Council Colorcon Qualifies as a Preferred Supplier with the National Animal Supplement Council
    Catalent, Edenbridge Pharma Enter Zydis Formulation Supply Agreement Catalent, Edenbridge Pharma Enter Zydis Formulation Supply Agreement
    Colorcon Adds New Containment Suite in Its Global Headquarters Colorcon Adds New Containment Suite in Its Global Headquarters
    Recro, Astex Enter Drug Development Alliance Recro, Astex Enter Drug Development Alliance
    HBC, Catalent Enter Innovative Softgel Alliance HBC, Catalent Enter Innovative Softgel Alliance
    Small Molecule Drug Development Trends Small Molecule Drug Development Trends
    Nanoform, Aprecia Partner to Advance 3DP Nanomedicines Nanoform, Aprecia Partner to Advance 3DP Nanomedicines
    Outsourcing Solid Dosage Manufacturing Outsourcing Solid Dosage Manufacturing

    Related Columns

    • Trust, but Verify

      Trust, but Verify

      Or, R.I.P, CoA.
      Emil W. Ciurczak, DoraMaxx Consulting 09.09.21

    • APIs | Drug Development
      API Development Trends

      API Development Trends

      Why is it important to consider solid form in API development?
      John Mykytiuk, Jamie Marshall and Andrew Blythe-Dickens, Sterling Pharma Solutions 09.09.21

    • APIs | Solid Dosage/Creams/Ointments
      Spray Drying: A Proven Approach to Enhance the Solubility of APIs

      Spray Drying: A Proven Approach to Enhance the Solubility of APIs

      Spray drying is an established particle engineering technology that offers several advantages over other methods used for improving API bioavailability.
      Benzion Dolitzky, PhD, VP R&D, Wavelength Pharmaceuticals 09.09.21


    • APIs | Clinical Trial Materials
      Outsourcing the Manufacture of Clinical Trial APIs

      Outsourcing the Manufacture of Clinical Trial APIs

      What to consider when deciding to partner with a CDMO for manufacturing.
      Josh Hoerner, General Manager, Purisys 09.09.21

    • Choosing and Managing a CDMO

      Choosing and Managing a CDMO

      Speed up your time-to-market, keep development costs under control and smooth the FDA approval and commercial launch process.
      Dana Toops, President, Avema Pharma Solutions 09.09.21

    Loading, Please Wait..
    Trending
    • Aurigene Expands Biologics CDMO Capacity
    • Astellas To Transfer Manufacturing Plant To Delpharm
    • Catalent Adds New Cryogenic Capabilities At Japanese Facility
    • Thermo Fisher Expands Steriles Facility In Asia-Pacific Region
    • Lifecore Biomedical Enters Into $150M New Financing Deal
    Breaking News
    • Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    • JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    • Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    • Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
    • Waters Corp. Acquires Light Scattering Company Wyatt Technology
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
    BGG Receives Patent for Saw Palmetto ID Method
    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Coatings World

    Latest Breaking News From Coatings World

    Brand Finance: Post-COVID Recovery Slows for Chemicals Industry Battling Energy Crisis
    BCF Calls for Greater Urgency on REACH Impasse
    MNYCA Hosts Afternoon Baseball Event
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CareDx, Miromatrix Collaborate on Bioengineered Organs Research
    Capitainer Releases to Market its Fully Automated Sample Handler
    Titan Medical Licenses Most IP to Intuitive; CEO Steps Down
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Stetson Introduces Men’s Grooming Portfolio
    Two Executives Depart from Unilever Amid CEO Transition
    L’Oréal Paris Welcomes Thuso Mbedu as Brand Ambassador
    Happi

    Latest Breaking News From Happi

    Shaz and Kiks Launches at Sephora
    Beautycounter Appoints Board Director Mindy Mackenzie Interim CEO
    Unilever Ventures’ Backs Selva Ventures in $34 Million Fund for Early-Stage CPG Brands
    Ink World

    Latest Breaking News From Ink World

    ACTEGA, Makro Labelling to Advance Signite Technology
    BCF Requests Greater Urgency on REACH Impasse
    Updated Method Published for Entire BASF Product Portfolio
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    ACTEGA teams with Makro Labelling to advance Signite technology
    Constantia Flexibles and SB Packagings commence joint venture
    Inland donates new VersaStudio printer to local high school
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mann+Hummel Names President Air Filtration Americas
    KNH Launches Eco-Friendly Menstrual Pads
    Niine Introduces India's First PLA-Based Sanitary Pads
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Enrollment Completed in Anika Therapeutics' Hyalofast Study
    Exactech Releases Next-Gen GPS Shoulder
    Data Shows Favorable Survivorship of MISHA Knee System & Reduction of Arthroplasty Risk in Patients
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    onsemi Presents Path to Accelerate Revenue Growth
    STMicroelectronics Introduces Waterproof MEMS Pressure Sensor
    Graphene Flagship to Join Euro Nano Forum 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login